http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016123163-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_babf53b950b3bf24a442d9f2f61d9724 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-8128 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2400-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-8132 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-56 |
| filingDate | 2016-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ae5f6966f6a5bb981198edfd6e6375c |
| publicationDate | 2016-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2016123163-A2 |
| titleOfInvention | Biomarkers of vascular disease |
| abstract | A biomarker panel including a four-panel test for clotting that detects soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), and plasminogen activator inhibitor (PAI-1). A biomarker panel including a three-panel test for glycocalyx integrity that detects syndecan-1 (SDC1), heparan sulfate (HS), and hyaluronidase (HAD). A biomarker panel including a test that detects a biomarker chosen from soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), plasminogen activator inhibitor (PAI-1), syndecan-1 (SDC1), heparan sulfate (HS), hyaluronidase (HAD), and combinations thereof. A kit including a biomarker panel, instructions for use, materials to take and apply samples to the panel, and descriptions of biomarker levels and their meaning. Methods of detecting the presence of vascular disease, determining the stage of vascular disease, monitoring the progress of vascular disease treatments, and monitoring the efficacy of drugs during drug development. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020053355-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114354937-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3623816-A1 |
| priorityDate | 2015-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 631.